IL149106A0 - Therapeutic use of selective pde10 inhibitors - Google Patents

Therapeutic use of selective pde10 inhibitors

Info

Publication number
IL149106A0
IL149106A0 IL14910602A IL14910602A IL149106A0 IL 149106 A0 IL149106 A0 IL 149106A0 IL 14910602 A IL14910602 A IL 14910602A IL 14910602 A IL14910602 A IL 14910602A IL 149106 A0 IL149106 A0 IL 149106A0
Authority
IL
Israel
Prior art keywords
therapeutic use
pde10 inhibitors
selective pde10
selective
inhibitors
Prior art date
Application number
IL14910602A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23092939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL149106(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL149106A0 publication Critical patent/IL149106A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14910602A 2001-04-20 2002-04-11 Therapeutic use of selective pde10 inhibitors IL149106A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28514801P 2001-04-20 2001-04-20

Publications (1)

Publication Number Publication Date
IL149106A0 true IL149106A0 (en) 2002-11-10

Family

ID=23092939

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14910602A IL149106A0 (en) 2001-04-20 2002-04-11 Therapeutic use of selective pde10 inhibitors

Country Status (13)

Country Link
US (1) US20030008806A1 (enEXAMPLES)
EP (1) EP1250923A3 (enEXAMPLES)
JP (1) JP3839343B2 (enEXAMPLES)
KR (2) KR20020082136A (enEXAMPLES)
CN (2) CN1840181A (enEXAMPLES)
AU (1) AU3440902A (enEXAMPLES)
CA (1) CA2382326A1 (enEXAMPLES)
HK (1) HK1048070A1 (enEXAMPLES)
HU (1) HUP0201310A3 (enEXAMPLES)
IL (1) IL149106A0 (enEXAMPLES)
NZ (1) NZ518478A (enEXAMPLES)
PL (1) PL353535A1 (enEXAMPLES)
ZA (1) ZA200203123B (enEXAMPLES)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10130151A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Neue Verwendung für PDE 10A-Inhibitoren
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US20060110783A1 (en) * 2002-11-08 2006-05-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
WO2004045508A2 (en) * 2002-11-15 2004-06-03 Merck & Co., Inc. Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
AR045696A1 (es) * 2003-06-30 2005-11-09 Altana Pharma Ag Derivados de pirrolodihidroisoquinolinas como inhibidores de pde10
ES2331519T3 (es) * 2003-06-30 2010-01-07 Nycomed Gmbh Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
EP1755611A1 (en) * 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
US20080161338A1 (en) * 2005-01-12 2008-07-03 Altana Pharma Ag Novel Pyrrolodihydroisoquinolines as Pde 10 Inhibitors
WO2007022280A1 (en) * 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2661850A1 (en) * 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
EP2060572A4 (en) * 2006-09-06 2010-11-17 Kyorin Seiyaku Kk PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODESTERASE INHIBITOR (PDE) WHICH CONTAINS IT AS ACTIVE MATTER
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
EP2348018A4 (en) * 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
EP2351748A4 (en) * 2008-10-09 2012-03-21 Kyorin Seiyaku Kk ISOCHINOLINE DERIVATIVES AND THESE PDE INHIBITORS CONTAINING ACTIVE SUBSTANCE
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
PH12012501643A1 (en) 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224100A1 (de) * 1982-06-29 1983-12-29 Michael 6950 Schriesheim Long Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
JP3276762B2 (ja) * 1993-12-28 2002-04-22 日本臓器製薬株式会社 イソキノリン誘導体を含有する医薬組成物
HUT71408A (en) * 1994-01-14 1995-11-28 Egyt Gyogyszervegyeszeti Gyar Pharmaceutical compositions containing papaverine for use to treatment of diseases related to glutamaterg neurotransmission
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
KR0177295B1 (ko) * 1996-02-28 1999-03-20 정명식 이소퀴놀린 화합물을 함유하는 항우울제
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EP1060251B1 (en) * 1998-02-23 2006-06-28 ICOS Corporation Phosphodiesterase 10
EP1218003A4 (en) * 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame

Also Published As

Publication number Publication date
JP2002363103A (ja) 2002-12-18
CN1840181A (zh) 2006-10-04
EP1250923A2 (en) 2002-10-23
EP1250923A3 (en) 2003-01-15
CA2382326A1 (en) 2002-10-20
HUP0201310A3 (en) 2008-10-28
NZ518478A (en) 2004-04-30
HU0201310D0 (enEXAMPLES) 2002-06-29
ZA200203123B (en) 2003-10-20
KR20020082136A (ko) 2002-10-30
US20030008806A1 (en) 2003-01-09
JP3839343B2 (ja) 2006-11-01
HK1048070A1 (zh) 2003-03-21
HUP0201310A2 (hu) 2003-02-28
KR20060002003A (ko) 2006-01-06
AU3440902A (en) 2002-10-24
CN1382490A (zh) 2002-12-04
PL353535A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
HUP0201310A3 (en) Therapeutic use of selective pde10 inhibitors
IL164778A0 (en) Therapeutic use of selective pde10 inhibitors
GB0025782D0 (en) Use of inhibitors
GB0111872D0 (en) Therapeutic agents and methods
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
EP1416995A4 (en) FILTERATION FLUID STERILIZATION DEVICE AND METHOD OF USE
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
HUP0300061A3 (en) Use of il-18 inhibitors
GB0118383D0 (en) Therapeutic methods
IL131047A0 (en) Use of il-18 inhibitors
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
GB0124124D0 (en) Methods of treatment
GB0119025D0 (en) Compounds and their therapeutic use
IL160230A0 (en) Use of il-18 inhibitors
GB0119370D0 (en) Therapeutic agent
ZA200205471B (en) Use of IL-18 inhibitors.
GB0128122D0 (en) Therapeutic use
GB2376943B (en) Compounds and their therapeutic use
GB0119460D0 (en) The use of inhibitors of the renin-angiotensin system
GB0112237D0 (en) Compounds and their therapeutic use
GB0123991D0 (en) New therapeutic use
GB0118627D0 (en) Use of compounds in therapy
GB0128123D0 (en) Therapeutic use
GB0106802D0 (en) Therapeutic use
GB0128088D0 (en) Therapeutic use